The 50-day moving average for BNTC moved below the 200-day moving average on October 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNTC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for BNTC entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for BNTC's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNTC advanced for three days, in 229 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
BNTC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.975) is normal, around the industry mean (26.782). P/E Ratio (2.890) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. BNTC's P/S Ratio (2500.000) is slightly higher than the industry average of (437.542).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. BNTC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DNLI saw its Momentum Indicator move below the 0 level on October 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In 81 of the 92 cases, the stock moved further down in the following days. The odds of a decline are at 88%.
The Moving Average Convergence Divergence Histogram (MACD) for DNLI turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 46 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNLI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for DNLI entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for DNLI's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNLI advanced for three days, in 211 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
DNLI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. DNLI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.016) is normal, around the industry mean (26.782). P/E Ratio (62.893) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (2.300) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNLI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
BNTC | DNLI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 59 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 82 Overvalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 98 | |
PRICE GROWTH RATING 1..100 | 87 | 62 | |
P/E GROWTH RATING 1..100 | 100 | 99 | |
SEASONALITY SCORE 1..100 | n/a | 29 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BNTC's Valuation (82) in the Biotechnology industry is in the same range as DNLI (90). This means that BNTC’s stock grew similarly to DNLI’s over the last 12 months.
BNTC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that BNTC’s stock grew similarly to DNLI’s over the last 12 months.
BNTC's SMR Rating (97) in the Biotechnology industry is in the same range as DNLI (98). This means that BNTC’s stock grew similarly to DNLI’s over the last 12 months.
DNLI's Price Growth Rating (62) in the Biotechnology industry is in the same range as BNTC (87). This means that DNLI’s stock grew similarly to BNTC’s over the last 12 months.
DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as BNTC (100). This means that DNLI’s stock grew similarly to BNTC’s over the last 12 months.
| BNTC | DNLI | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 76% |
| Stochastic ODDS (%) | 3 days ago 88% | 1 day ago 82% |
| Momentum ODDS (%) | N/A | 1 day ago 88% |
| MACD ODDS (%) | N/A | 1 day ago 87% |
| TrendWeek ODDS (%) | 1 day ago 88% | 1 day ago 84% |
| TrendMonth ODDS (%) | 1 day ago 88% | 1 day ago 82% |
| Advances ODDS (%) | 5 days ago 84% | 25 days ago 79% |
| Declines ODDS (%) | 3 days ago 89% | 3 days ago 81% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 77% |
| Aroon ODDS (%) | 1 day ago 88% | 1 day ago 82% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BNTC’s FA Score shows that 0 FA rating(s) are green while DNLI’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BNTC’s TA Score shows that 4 TA indicator(s) are bullish while DNLI’s TA Score has 4 bullish TA indicator(s).
BNTC (@Biotechnology) experienced а -8.57% price change this week, while DNLI (@Biotechnology) price change was -9.46% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.
DNLI is expected to report earnings on Nov 11, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GGN | 5.26 | 0.02 | +0.38% |
| GAMCO Global Gold Natural Resources & Income Trust | |||
| APMU | 24.29 | N/A | N/A |
| ActivePassive Intermediate Municipal Bond ETF (APMU) | |||
| XLV | 176.71 | -0.48 | -0.27% |
| State Street Health Care Select Sector SPDR ETF (XLV) | |||
| MCH | 25.60 | -0.22 | -0.83% |
| Matthews China Active ETF (MCH) | |||
| KARS | 25.93 | -0.57 | -2.16% |
| KraneShares Electric Vehicles & Future Mobility Index ETF (KARS) | |||
A.I.dvisor indicates that over the last year, BNTC has been loosely correlated with VIR. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BNTC jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To BNTC | 1D Price Change % | ||
|---|---|---|---|---|
| BNTC | 100% | -4.14% | ||
| VIR - BNTC | 46% Loosely correlated | -4.87% | ||
| EDIT - BNTC | 45% Loosely correlated | -3.69% | ||
| KYTX - BNTC | 44% Loosely correlated | -5.03% | ||
| BEAM - BNTC | 43% Loosely correlated | -5.10% | ||
| DNLI - BNTC | 42% Loosely correlated | -3.98% | ||
More | ||||